









Markets
/
Stocks
/
nasdaq-mck
/

Mckesson Corp

MCK

825.765USD

+18.135+2.25%

Close 10/30, 16:00（ET）Quotes delayed by 15 min

103.22BMarket Cap

32.62P/E TTM



Mckesson Corp

825.765

+18.135+2.25%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Mckesson Corp

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Mckesson Corp's Score

Industry at a Glance

Industry Ranking

5 / 160

Overall Ranking

26 / 4623

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 18 analysts

Buy

Current Rating

837.446

Target Price

+4.08%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Mckesson Corp Highlights

StrengthsRisks

McKesson Corporation is a provider of diversified healthcare services. It is engaged in advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over the counter (OTC) pharmaceutical drugs and other healthcare-related products in the United States. Its Prescription Technology Solutions segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Its Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home healthcare agencies. Its International segment includes its operations in Norway, which provides distribution and services to wholesale and retail customers.

Industry Leader

The company's revenue leads the industry, with the latest annual revenue totaling USD 359.05B.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 29.76% year-on-year.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 10.68%.

Overvalued

The company’s latest PE is 32.19, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 112.13M shares, decreasing 2.77% quarter-over-quarter.

Held by Brandes Investmen

Star Investor Brandes Investmen holds 177.22K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.19.

Financial Health

Currency: USD Updated: 2025-10-29

The company's current financial score is 6.82, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 97.83B, representing a year-over-year increase of 23.39%, while its net profit experienced a year-over-year increase of 14.32%.

Score

Industry at a Glance

Previous score

6.82

Change



Financials

8.12

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

5.64

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.64

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.40

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

5.28

Key Metrics

Free cash flow

No Data

Mckesson Corp's Company Valuation

Currency: USD Updated: 2025-10-29

The company’s current valuation score is 8.51, which is higher than the Pharmaceuticals industry's average of 7.22. Its current P/E ratio is 32.19, which is 0.47% below the recent high of 32.34 and 56.41% above the recent low of 14.03.

Score

Industry at a Glance

Previous score

8.51

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 5/160

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-29

The company’s current earnings forecast score is 8.33, which is higher than the Pharmaceuticals industry's average of 7.79. The average price target for Mckesson Corp is 853.00, with a high of 920.00 and a low of 641.24.

Score

Industry at a Glance

Previous score

8.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 18 analysts

Buy

Current Rating

837.446

Target Price

+3.69%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

McKesson Corp

MCK

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-29

The company’s current price momentum score is 9.62, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 836.87 and the support level at 754.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.53

Change

0.09

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

3.245

Buy

RSI(14)

72.475

Buy

STOCH(KDJ)(9,3,3)

77.516

Neutral

ATR(14)

17.034

Low Volatility

CCI(14)

205.764

Overbought

Williams %R

22.152

Buy

TRIX(12,20)

0.403

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

810.172

Buy

MA10

800.056

Buy

MA20

781.303

Buy

MA50

739.291

Buy

MA100

723.383

Buy

MA200

692.049

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-29

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 5.79. The latest institutional shareholding proportion is 90.14%, representing a quarter-over-quarter increase of 0.34%. The largest institutional shareholder is The Vanguard, holding a total of 12.01M shares, representing 9.66% of shares outstanding, with 2.89% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

12.01M

+1.95%

BlackRock Institutional Trust Company, N.A.

6.74M

+2.60%

State Street Investment Management (US)

5.70M

+0.10%

MFS Investment Management

3.92M

-13.58%

JP Morgan Asset Management

3.45M

+12.28%

Geode Capital Management, L.L.C.

2.82M

+4.14%

Putnam Investment Management, L.L.C.

2.27M

-6.82%

AllianceBernstein L.P.

2.27M

+150.44%

Fidelity Management & Research Company LLC

1.91M

+39.37%

Norges Bank Investment Management (NBIM)

1.84M

-12.75%

Risk Assessment

Currency: USD Updated: 2025-10-29

The company’s current risk assessment score is 9.52, which is higher than the Pharmaceuticals industry's average of 5.13. The company's beta value is 0.51. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.